Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$20.88 -0.3%	$20.39	$13.40 ▼ $25.23	$3.51B	0.64	1.98 million shs	2.02 million shs
ALVO Alvotech	$9.02 -1.8%	$9.70	$7.35 ▼ $13.70	$2.77B	0.11	144,722 shs	179,971 shs
BPMUF Basilea Pharmaceutica	$61.34	$52.35	$47.50 ▼ $61.34	$807.83M	0.29	0 shs	N/A
OGN Organon & Co.	$9.74 -2.2%	$9.55	$8.01 ▼ $23.10	$2.59B	0.6	3.54 million shs	2.59 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	0.00%	-5.29%	-4.69%	+43.39%	+29.88%
ALVO Alvotech	0.00%	+0.55%	-13.79%	+10.46%	-24.17%
BPMUF Basilea Pharmaceutica	0.00%	+6.31%	+6.31%	+13.59%	+27.39%
OGN Organon & Co.	0.00%	+2.09%	+5.39%	-19.63%	-49.90%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACAD ACADIA Pharmaceuticals	4.6273 of 5 stars	4.4	3.0	0.0	0.0	2.6	4.2	2.5
ALVO Alvotech	3.7357 of 5 stars	3.5	4.0	0.0	0.0	3.3	0.0	1.3
BPMUF Basilea Pharmaceutica	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OGN Organon & Co.	4.8944 of 5 stars	3.3	4.0	1.7	3.7	1.8	3.3	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.71	Moderate Buy	$27.88	33.50% Upside
ALVO Alvotech	3.00	Buy	$18.00	99.56% Upside
BPMUF Basilea Pharmaceutica	4.00	Strong Buy	N/A	N/A
OGN Organon & Co.	2.50	Moderate Buy	$18.00	84.80% Upside

Current Analyst Ratings Breakdown

Latest BPMUF, OGN, ACAD, and ALVO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	ACAD ACADIA Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform	$19.00 ➝ $22.00
6/26/2025	ACAD ACADIA Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$37.00
6/26/2025	ACAD ACADIA Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
6/26/2025	ACAD ACADIA Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00
6/23/2025	ACAD ACADIA Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$26.00 ➝ $38.00
6/6/2025	ACAD ACADIA Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$26.00 ➝ $30.00
6/5/2025	ACAD ACADIA Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/5/2025	ACAD ACADIA Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Hold	$18.00 ➝ $23.00
5/22/2025	OGN Organon & Co.	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/21/2025	ACAD ACADIA Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$20.00 ➝ $35.00
5/20/2025	ACAD ACADIA Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$20.00 ➝ $24.00

(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$957.80M	3.65	$0.70 per share	29.72	$4.40 per share	4.75
ALVO Alvotech	$491.98M	5.53	N/A	N/A	($1.37) per share	-6.58
BPMUF Basilea Pharmaceutica	$236.92M	3.41	$6.85 per share	8.96	$6.99 per share	8.78
OGN Organon & Co.	$6.40B	0.40	$4.82 per share	2.02	$1.83 per share	5.32

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	$226.45M	$1.37	15.24	27.47	4.51	22.97%	17.46%	10.75%	8/5/2025 (Estimated)
ALVO Alvotech	-$231.86M	$0.37	24.38	45.10	N/A	16.42%	-36.37%	12.70%	8/21/2025 (Estimated)
BPMUF Basilea Pharmaceutica	$88.14M	N/A	0.00	∞	N/A	N/A	N/A	N/A	8/11/2025 (Estimated)
OGN Organon & Co.	$864M	$2.88	3.38	2.60	1.02	11.92%	227.43%	7.34%	8/5/2025 (Estimated)

Latest BPMUF, OGN, ACAD, and ALVO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2025	Q1 2025	ACAD ACADIA Pharmaceuticals	$0.10	$0.11	+$0.01	$0.11	$239.32 million	$244.32 million
5/7/2025	Q1 2025	ALVO Alvotech	-$0.17	$0.35	+$0.52	$0.35	N/A	N/A
5/1/2025	Q1 2025	OGN Organon & Co.	$0.89	$1.02	+$0.13	$0.33	$1.53 billion	$1.51 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ALVO Alvotech	N/A	N/A	N/A	N/A	N/A
BPMUF Basilea Pharmaceutica	N/A	N/A	N/A	N/A	N/A
OGN Organon & Co.	$0.08	0.82%	N/A	2.78%	N/A

Latest BPMUF, OGN, ACAD, and ALVO Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/2/2025	OGN Organon & Co.	quarterly	$0.02	0.8%	5/12/2025	5/12/2025	6/12/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	2.88	2.80
ALVO Alvotech	N/A	1.73	1.19
BPMUF Basilea Pharmaceutica	1.18	4.85	4.16
OGN Organon & Co.	16.49	1.67	1.15

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
ALVO Alvotech	N/A
BPMUF Basilea Pharmaceutica	N/A
OGN Organon & Co.	77.43%

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	28.30%
ALVO Alvotech	N/A
BPMUF Basilea Pharmaceutica	N/A
OGN Organon & Co.	1.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	167.36 million	120.00 million	Optionable
ALVO Alvotech	1,032	301.48 million	N/A	Not Optionable
BPMUF Basilea Pharmaceutica	147	13.17 million	N/A	Not Optionable
OGN Organon & Co.	4,000	259.96 million	256.32 million	Not Optionable

BPMUF, OGN, ACAD, and ALVO Headlines

Recent News About These Companies

OGN SHAREHOLDER ALERT: Suffer Losses on Organon & Co.? Contact BFA Law by July 22 Securities Fraud Class Action Deadline (NYSE:OGN) - Morningstar

1 hour ago | morningstar.comM

With 79% ownership of the shares, Organon & Co. (NYSE:OGN) is heavily dominated by institutional owners

1 hour ago | finance.yahoo.com

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Organon & Co. Investors to Secure Counsel Before Important Deadline in Securities Class Action – OGN

July 7 at 5:12 PM | globenewswire.com

Organon & Co. Sued for Securities Law Violations - Contact The Gross Law Firm Before July 22, 2025 to Discuss Your Rights – OGN

July 7 at 4:45 PM | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Organon & Co. of Class Action Lawsuit and Upcoming Deadlines - OGN

July 7 at 2:45 PM | prnewswire.com

ORGANON & CO. (NYSE: OGN) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Organon & Co. Investors of Upcoming Deadline

July 7 at 11:14 AM | globenewswire.com

OGN Shareholders Have the Right to Lead the Organon & Co. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - OGN

July 7 at 10:10 AM | prnewswire.com

OGN Investors Have Opportunity to Lead Organon & Co. Securities Fraud Lawsuit with the Schall Law Firm

July 7 at 10:08 AM | prnewswire.com

The Gross Law Firm Notifies Organon & Co. Investors of a Class Action Lawsuit and Upcoming Deadline - OGN

July 7 at 9:00 AM | prnewswire.com

Organon's VTAMAÂ® (tapinarof) cream, 1%, Granted Strong Recommendation in the American Academy of Dermatology Updated 2025 Guidelines for Adult Atopic Dermatitis

July 7 at 8:05 AM | businesswire.com

OGN Investors Have Opportunity to Lead Organon & Co. Securities Fraud Lawsuit

July 6 at 8:14 PM | gurufocus.com

OGN Investors Have Opportunity to Lead Organon & Co. Securities Fraud Lawsuit

July 6 at 7:23 PM | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Organon & Co. of Class Action Lawsuit and Upcoming Deadlines - OGN

July 6 at 10:00 AM | globenewswire.com

OGN SHAREHOLDER ALERT: Suffer Losses on Organon & Co. ...

July 6 at 8:40 AM | gurufocus.com

OGN SHAREHOLDER ALERT: Suffer Losses on Organon & Co.? Contact BFA Law by July 22 Securities Fraud Class Action Deadline (NYSE:OGN)

July 6 at 7:46 AM | globenewswire.com

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon

July 6 at 7:40 AM | globenewswire.com

Allspring Global Investments Holdings LLC Sells 397,631 Shares of Organon & Co. (NYSE:OGN)

July 6 at 3:35 AM | marketbeat.com

Organon & Co. (NYSE:OGN) Shares Bought by Acorn Financial Advisory Services Inc. ADV

July 5 at 8:50 AM | marketbeat.com

OGN SHAREHOLDER NOTICE: Organon & Co. Investors are Notified to Contact BFA Law about the Pending Class Action Lawsuit by July 22

July 5 at 8:21 AM | markets.businessinsider.com

ORGANON SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Organon & Co. - OGN

July 4 at 10:51 PM | prnewswire.com

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Organon & Co. ...

July 4 at 6:07 PM | gurufocus.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Investors Are Waking Up to Arista Networks—Here’s the Scoop
By Jeffrey Neal Johnson | June 26, 2025
View Investors Are Waking Up to Arista Networks—Here’s the Scoop

BPMUF, OGN, ACAD, and ALVO Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$20.88 -0.07 (-0.33%)

As of 04:00 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Alvotech NASDAQ:ALVO

$9.02 -0.17 (-1.85%)

Closing price 04:00 PM Eastern

Extended Trading

$9.01 -0.01 (-0.11%)

As of 07:57 PM Eastern

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Basilea Pharmaceutica OTCMKTS:BPMUF

$61.34 0.00 (0.00%)

As of 07/3/2025

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as offers treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. Further, it offers Fosmanogepix, an antifungal drug for the treatment of Candidemia which in Phase II clinical trials. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.

Organon & Co. NYSE:OGN

$9.74 -0.22 (-2.21%)

Closing price 03:59 PM Eastern

Extended Trading

$9.76 +0.02 (+0.16%)

As of 08:00 PM Eastern

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time